NSCLC

This phase 2 trial is testing whether a three-pronged approach—tumor ablation, immunotherapy (tislelizumab), and chemotherapy—can improve outcomes for people with stage II-IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if this combination can e…

This phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side ef…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on can…

This study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard…

This phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays und…

This Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction…

This Phase 2 trial tests whether adding the antihistamine diphenhydramine to the immunotherapy drug toripalimab and standard chemotherapy helps shrink tumors more effectively in people with operable non-small cell lung cancer. About 120 participants will receive either the combin…

This phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…

This Phase 3 trial tests whether adding an experimental drug called SYS6010 to the standard treatment osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 participants will be random…

This phase 2 trial tests whether adding an experimental immunotherapy (iparomlimab and tuvonralimab) to targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 people with stage I-IIB disease will receive the drug every 3 weeks for a year, star…

This phase 2 trial tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer that does not have certain gene mutations. Participants will receive the drug combination before su…

This study tests a device that uses both cold and radiofrequency to treat lung tumors during a standard bronchoscopy. Twenty people with early-stage lung cancer will receive the treatment before surgical removal of the tumor. The goal is to see if the device can safely and effect…

This study looks at how safe and effective the drug SHR-A1811 is for Chinese patients with advanced or spreading non-small cell lung cancer that has a specific genetic change called HER2 alteration. About 1,000 adults will be followed as they receive the drug as part of their nor…

This study tests a new targeted cancer pill called limertinib combined with brain radiation as a first treatment for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. The goal is to see if the combination can better control the brain tum…

This phase 2 trial tests iruplinalkib tablets as a daily treatment after surgery for people with stage IA ALK-positive non-small cell lung cancer who have high-risk factors. The goal is to see if the drug can prevent the cancer from coming back. About 28 participants will take th…

This study tests two drugs (SHR-A1811 and adebelimumab) given before surgery to people with early-stage non-small cell lung cancer that has a specific genetic change (HER2 alteration). The goal is to see if the combination can shrink or eliminate the tumor before it is removed. A…

This trial tests a new approach for people with early-stage non-small cell lung cancer that can be removed with surgery. Before surgery, patients receive a combination of targeted radiation (SBRT), two immunotherapy drugs (iparomlimab and tuvonralimab, also called QL1706), and ch…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new approach for people with early-stage lung cancer who cannot or will not take chemotherapy. Before surgery, patients receive a short course of focused radiation (SBRT) combined with immunotherapy (tislelizumab) and an antiangiogenic drug (anlotinib). The goa…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This phase 2 trial tests the drug Vebreltinib, taken as a pill for 8 weeks before surgery, in 30 people with stage IIA-IIIB non-small cell lung cancer that has a specific gene change (MET exon 14 skipping). The goal is to see if the drug can shrink tumors enough to improve surger…

This phase 2 trial tests whether the targeted drug bozitinib, combined with standard chemotherapy, can shrink tumors before surgery in people with stage IIA to IIIC non-small cell lung cancer that has a specific MET gene change. About 34 participants will receive the drug combo f…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study tests whether a short, intensive psychological program before lung cancer surgery can lower anxiety and depression. About 138 adults scheduled for lung cancer surgery will be split into three groups: one receiving four weekly therapy sessions, one refusing support, and…

This phase 1 trial investigates how HS-10504, an experimental drug for EGFR-mutant non-small cell lung cancer, changes the way the body processes midazolam, a common sedative. About 24 patients with advanced lung cancer who have stopped responding to standard EGFR-targeted therap…

This early study tests whether applying low-intensity electric fields (TTFields) to the chest before lung cancer surgery is safe and affects cancer-related genes. About 18 adults with stage I-IIIA non-small cell lung cancer will wear a non-invasive device for a short time before …

This study looks at 300 lung cancer patients who had immunotherapy before surgery but still had cancer cells left after the operation. Researchers will use advanced gene testing to find hidden genetic changes that might explain why the cancer didn't fully disappear. The goal is t…